Halucenex is a Psychedelic-Assisted Psychotherapy (PAP) company

• Halucenex focuses on the commercialisation and R&D of novel psychedelic molecules for the treatment of Post Traumatic Stress Disorder (PTSD), Depression and other mental illnesses
• Agreement provides Creso Pharma with entry into the emerging global market for psychedelics medicines – estimated to be worth up to US$100Bn
• Acquisition marks the first 100%-owned psychedelic medicines company on the ASX
• PTSD therapeutics market is expected to grow to US$10.5Bn by 2025 and mental illness in Canada has an economic burden of C$51Bn per annum,
• Halucenex operates a 6,000 sq. ft. medical clinic dedicated to the treatment of mental illness located adjacent to an emergency hospital
• On receipt of its Dealer’s License, Halucenex will be permitted to possess and conduct R&D of psychedelic molecules including psilocybin
• Focused on synthetic psilocybin, the active ingredient in magic mushrooms which has been shown to have considerable evidence-based mental health benefits
• Path to early revenues through strategic affiliation with Veterans Affairs Canada and Veteran support groups via veteran and advisor David Fraser, retired NATO general
• Multiple near-term value catalysts – licencing deals and clinical trial milestones pending
• Delivers a new highly lucrative industry vertical and additional future revenue stream
• Highly experienced team with a track record of commercialising successful businesses
• Halucenex will benefit from significant synergies including Creso Pharma’s experienced pharmaceutical product development team, industry leading advisers, a comprehensive global distribution network and a top-tier premium cannabis cultivation facility

Creso Pharma Limited (ASX:CPH, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to advise that it has signed an agreement to acquire Halucenex Life Sciences Inc. (“Halucenex”), an established psychedelics company focused on developing treatments for Treatment Resistant Depression in individuals suffering from PTSD, and other mental health illnesses (Acquisition).

Based in Nova Scotia, Canada, Halucenex is a life sciences development company focused on researching, developing and licensing novel psychedelic molecules for the global pharmaceutical and nutraceutical markets. Halucenex is currently focused on progressing clinical trials to research the efficacy of psilocybin to treat and alleviate Treatment Resistant Depression in individuals suffering from PTSD and other mental illnesses.

The proposed acquisition provides Creso Pharma with a first mover advantage into the psychedelic medicines sector and marks the first 100%-owned psychedelic medicines company listed on the ASX.

The acquisition of Halucenex is transformational for Creso Pharma. The Company will emerge as a best-in-class provider of cannabis, cannabinoids and psychedelics alternative medicines to meet the large unmet need for treatments to improve mental health and well being.

Halucenex – an established Canadian psychedelics company:

Halucenex is focused on delivering and developing evidence-based products for the treatment of Treatment Resistant Depression and other detrimental mental illnesses, with a specific focus on psychedelic-derived medicines.

The company operates at 6,000 sq. ft. medical treatment facility in Nova Scotia, Canada, located next to the Hants Emergency Hospital, with a Controlled Substances laboratory, and 18 treatment rooms dedicated to providing psychedelic-assisted psychotherapy.